Ascend is a specialist AAV development partner with the mission to support the next-generation of life-science innovators in bringing gene therapy products to patients. Our team of experts offer unparalleled insight and collaboration in delivering your products from the bench through the clinic and beyond. 

With scientific innovation and quality at the core of our business, our transatlantic team of industry experts strive to support you at any stage of your developmental journey. From our world-class analytical toolkit to our highly scalable AAV platform and next-gen technologies, we take pride in delivering both high-yielding and high-quality products. 

Let’s aim higher and develop the next wave of accessible life-saving therapies together.




Ascend  

It's great to be onsite, and close to "home" here in beautiful #Munich for #bioeurope. Are you interested in having a chat about #genetherapy? Feel free to say hello to Jason King and Matthias Lee-Hifler on the floor, or DM us any time. 

https://lnkd.in/dnuNZ2D

We all know that it can be a true challenge to reduce or eliminate "empty" capsids in #downstreamprocessing in a #scalable manner. But what if there was a fully scalable method to efficiently enrich the percentage of full capsids by anion exchange chromatography? 

#Register to join our own Regina Staffler and Nelis Denys of Unchained Labs as they present a discussion with #data on this topic on 13 November at 8am Pacific.

November is officially here, which means we are off to #bioeurope next! Matthias Lee-Hifler and Jason King will be onsite (and close to home in beautiful #Munich) representing the team and ready to talk all things AAV and #genetherapy. Find us in the #partnering app or shoot us a DM here to set time. 

It's spooky how fast October went! But what a "treat" to see all these BOO-tiful people having fun and supporting #cellandgenetherapy #innovation  in Brussels last week at the European Society of Gene and Cell Therapy Congress. 

And we still have one more "trick" left in our bag as the tradeshow season comes to a close. Next week, Jason King and Matthias Lee-Hifler, will be close to our "haunt" in Munich for the EBD Group #BIOEUROPE event. 

Will you be there? We'd love to see you. 

Or find more about our what we have been brewing in our "cauldron" here: https://lnkd.in/eMwfWbHg 

Are you at the European Society of Gene and Cell Therapy Congress wondering how to solve stability and #delivery challenges early in your #genetherapy #development program? Philipp Beck has an answer for that! Find him at poster P95 tonight in the Gare Maritime Hall to chat about it, or send us a DM any time. 

DMARC

DNSSEC

Microsoft Exchange Online

Office 365 Mail

Microsoft Azure DNS

Pound Sterling

Squarespace Hosted

Google Domains

Google DNS

Senior Director of Research

Chris Reid

Chief Operating Officer

Arjan Roozen

Engineering

Kevin Moulton

VP & Site Head, Discovery Biology

Mo Mandegar

Chief Financial Officer

Wes McConnell

Tim Funnell

Director & Interim CEO

United Kingdom Companies With Fewer Than 1000 Employees (Top 10K)

Europe, Middle East, and Africa (EMEA) Biotechnology Companies (Top 10K)

Europe Consulting Companies (Top 10K)

Biotechnology Companies With Fewer Than 1000 Employees (Top 10K)

Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.

Abingworth

Petrichor Healthcare Capital Management

Series A - Ascend Gene & Cell Therapies

Venture Round - Ascend Gene & Cell Therapies

Potters Bar

Hertford

United Kingdom

Europe

Ascend Gene & Cell Therapies

CDMO Ascend links up with gene therapy firm Beacon Therapeutics

Ascend acquires GMP manufacturing capacity in Alachua, Florida; Enters long-term partnership with Beacon ...

Ascend Acquires Florida Facility and Expertise, Bolstering Gene Therapy Development

4BIO Capital Portfolio Company Ascend Acquires Florida-Based GMP Manufacturing Capacity

Biotech investment in UK ticks up in Q2

European VC deal value down 61% in first half of 2023, report ...

Ascend Gene & Cell Therapies is a gene and cell therapy manufacturing specialist that has recently secured a significant £106 million Series A funding round. The company aims to improve therapies by constantly refining and innovating its approach, with a focus on creating effective gene therapies to a world-class standard. Ascend supports manufacturing and process development projects from design through to clinical and commercial scales, and it prioritizes communication, transparency, and building lasting trust with its partners.

Workable provides recruiting software and a hiring platform that allows users to find, hire, onboard, and manage employees.

Workable

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Oct 29, 2024 5:10 PM	51a6f540
crunchbase profile	general	Oct 30, 2024 4:48 AM	2f3b4c96
li profile	general	Feb 6, 2024 9:06 AM	373af2bb
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	20daa2d1
peers	general	Feb 6, 2024 9:06 AM	3a414798
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ASCEND-GCTX

Workable